UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 22, 2014
EPIZYME, INC.
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
|
|
Delaware
|
|
001-35945
|
|
26-1349956
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
400 Technology Square, Cambridge, Massachusetts
|
|
02139
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (617) 229-5872
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On April 22, 2014, Epizyme, Inc. (the “Company”) announced that it had
achieved a lead candidate milestone for the third target in its collaboration with Glaxo Group Limited, an affiliate of GlaxoSmithKline, or GSK, and received $4.0 million in milestone and license payments. The full text of the press release issued
in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The license payments received by the Company were in consideration for amending certain terms of the
collaboration agreement for the third licensed target under the collaboration agreement, including revising the license terms with respect to candidate compounds and amending the corresponding financial terms. Following this milestone achievement
and collaboration agreement amendment, the Company is eligible to receive up to $18.0 million in additional substantive preclinical research and development milestone payments, up to $109.0 million in clinical development milestone payments, up to
$275.0 million in regulatory milestone payments and up to $218.0 million in sales-based milestone payments.
The information provided under this
Item 8.01 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
|
|
|
|
|
10.1
|
|
Amendment to Collaboration and License Agreement dated as of February 24, 2014 by and between the Registrant and Glaxo Group Limited
|
|
|
|
|
10.2
|
|
Amendment to Collaboration and License Agreement dated as of March 18, 2014 by and between the Registrant and Glaxo Group Limited
|
|
|
|
The following exhibit relating to Item 8.01 shall be deemed to be furnished, and not filed:
|
|
|
|
|
|
99.1
|
|
Press release issued by the Company on April 22, 2014
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
EPIZYME, INC.
|
|
|
|
|
|
|
Date: April 22, 2014
|
|
|
|
By:
|
|
/s/ Jason P. Rhodes
|
|
|
|
|
|
|
|
Jason P. Rhodes
President, Chief Financial
Officer and Treasurer
|
EXHIBIT INDEX
|
|
|
|
|
Exhibit
Number
|
|
Description of Exhibit
|
|
|
|
|
10.1†
|
|
Amendment to Collaboration and License Agreement dated as of February 24, 2014 by and between the Registrant and Glaxo Group Limited
|
|
|
|
|
10.2†
|
|
Amendment to Collaboration and License Agreement dated as of March 18, 2014 by and between the Registrant and Glaxo Group Limited
|
|
|
|
|
99.1
|
|
Press release issued by the Company on April 22, 2014
|
|
†
|
Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.
|
Exhibit 10.1
|
|
|
|
|
|
|
|
|
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Double asterisks denote omissions.
|
|
|
Amendment to
Collaboration and License Agreement
This Amendment (this “
Amendment
”) to the Collaboration and License Agreement dated as of February 20, 2014 and
previously amended on July 23, 2013 (collectively, the “
Agreement
”), by and between EPIZYME and GSK is effective as of the date of last signature below (the “Amendment Effective Date”). Capitalized terms used but not
defined herein shall have the meanings ascribed to such terms in the Agreement.
WHEREAS, pursuant to the Agreement, the Parties agreed to
conduct certain Development activities including activities with respect to the Selected Target [**] under a Research Plan, and EPIZYME granted to GSK an exclusive worldwide license to Develop and Commercialize certain compounds directed to the
Selected Target [**],
WHEREAS, the Parties desire to clarify and supplement the activities of the Parties under the Research Plan.
NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties,
intending to be legally bound, hereby agree as follows:
1.
Amendment of Section 4.3
. Section 4.3 of the
Agreement is hereby amended by inserting the following new Section 4.3.1 immediately following Section 4.3 of the Agreement:
4.3.1
Disclosure of Licensed Compound Structures
. Notwithstanding anything to the contrary in the Agreement, including
Articles 4, 5, and 6, the Parties agree that:
(a) EPIZYME will waive the right to redact the chemical structure of any
Compound prior to such Compound’s achievement of the Lead Candidate Criteria for all compounds directed to [**] that meet the Licensed Compound definition of Section 1.63 of the Agreement. Disclosure of the chemical structures of all such
Licensed Compounds determined as of the Amendment Effective Date will occur immediately. Disclosure of the chemical structures of all Licensed Compounds determined from and after the Amendment Effective Date and prior to Development Candidate
Selection (or the end of the Research Term if prior to Development Candidate Selection) will occur on a regular schedule every [**] after the Amendment Effective Date. For the avoidance of doubt, from and after the Amendment Effective Date and prior
to Development Candidate Selection (or the end of the Research Term if prior to Development Candidate Selection), GSK and its Affiliates and Sublicensees shall not conduct any chemistry activities based on the chemical structures of the Licensed
Compounds.
(b) Any compounds derived from chemistry activities conducted by GSK or its Affiliates or Sublicensees prior to
Development Candidate Selection (or the end of the Research Term if prior to Development Candidate Selection) based on the chemical structures of Licensed Compounds disclosed to GSK by EPIZYME under subsection (a) above, shall be deemed to be
EPIZYME IP for all purposes under the Agreement.
2.
Miscellaneous
. The Parties hereby confirm and agree that, as
amended herein, the Agreement remains in full force and effect. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures
and signatures transmitted via PDF shall be treated as original signatures.
IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly
authorized representatives.
|
|
|
|
|
|
|
|
|
|
|
EPIZYME, INC.
|
|
|
|
GLAXO GROUP LIMITED
|
|
|
|
|
|
|
|
By:
|
|
/s/ Jason Rhodes
|
|
|
|
By:
|
|
/s/ RK Prinjha
|
|
Name:
|
|
Jason Rhodes
|
|
|
|
Name:
|
|
RK Prinjha
|
|
Title:
|
|
President & CFO
|
|
|
|
Title:
|
|
VP Head Epinova DPU, GSK
|
|
Date:
|
|
2/24/14
|
|
|
|
Date:
|
|
21
st
February 2014
|
Exhibit 10.2
|
|
|
|
|
|
|
|
|
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Double asterisks denote omissions.
|
|
|
Execution Copy
Amendment No. 3 to
Collaboration and License Agreement
This Amendment No. 3 (this “
Amendment No. 3
”) to the Collaboration and License Agreement dated as of
January 8, 2011 and previously amended on July 23, 2013 and February 24, 2014 (as so amended, the “
Agreement
”), by and between Epizyme, Inc., a Delaware corporation having its principal place of business at 400
Technology Square, 4
th
Floor, Cambridge, Massachusetts 02139 USA (“EPIZYME”) and Glaxo Group Limited, a company existing under the laws of England, having its registered office at Glaxo
Wellcome House, 980 Great West Road, Brentford, Middlesex, TW8 9GS, England (“GSK”) is effective as of March 18, 2014 (the “
Amendment No. 3 Effective Date
”). Capitalized terms used but not defined herein shall
have the meanings ascribed to such terms in the Agreement.
WHEREAS, the Parties desire to amend certain terms of the Agreement relating
to the Selected Target(s) [**] and [**];
NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good
and valuable consideration, the Parties, intending to be legally bound, hereby agree as follows:
|
|
1.
|
Amendment of Development Candidate Selection Criteria for Compounds Directed to [**] and [**].
The Development Candidate Selection Criteria for Compounds directed to [**]and [**] are hereby amended and restated
in their entirety as set forth on
Exhibit A
hereto. The Development Candidate Selection Criteria shall remain as set forth in the Agreement immediately prior to the Amendment No. 3 Effective Date with respect to Selected Targets other
than [**] and [**].
|
2.
Amendment of Licensed Compound Definition for Compounds Directed to [**].
The
“Licensed Compound” definition for Compounds directed to [**] is hereby amended and restated in its entirety to read as follows:
““
Licensed Compound(s)
” means any Compound that is:
(a) synthesized or identified by either Party (or by any of its respective Affiliates or any Third Party working with or on behalf of such
Party or any of its respective Affiliates) in the conduct of the Collaboration;
(b) determined to have both an in vitro IC50 enzymatic
potency and an RGG cellular assay EC30 potency of less than or equal to [**] with respect to [**]; and
(c) for any Compound synthesized
or identified by EPIZYME, covered generically or specifically under the Patents listed in
Exhibit B
. For clarity, for purposes of this definition only, Compounds not covered generically or specifically under the Patents listed in
Exhibit
B
, but covered generically or specifically under other EPIZYME patent filings shall be deemed to have been synthesized or identified by EPIZYME and not by GSK, and such Compounds shall not be considered Licensed Compounds unless otherwise agreed
by EPIZYME.”
The “Licensed Compound(s)” definition shall remain as set forth in the Agreement
immediately prior to the Amendment No. 3 Effective Date with respect to Compounds directed to Selected Targets other than [**].
|
|
3.
|
Amendments to Financial and Diligence Terms of the Agreement Relating to [**].
|
|
|
a.
|
In partial consideration for the rights and licenses granted to GSK, including the amendments thereto set forth in this Amendment No. 3, GSK shall pay to EPIZYME a non-refundable, non-creditable payment of Three
Million U.S. Dollars (US$3,000,000). Such payment shall be payable by wire transfer of immediately available funds in accordance with wire transfer instructions of EPIZYME provided in writing to GSK on or prior to the Amendment No. 3 Effective
Date. Such payment shall be made within [**] Business Days after GSK’s receipt of an invoice from EPIZYME on or after the Amendment No. 3 Effective Date, which invoice shall be sent in PDF format to [**] with a copy to [**].
|
|
|
b.
|
The Parties hereby agree to and adopt the amended and restated Research Plan and the budget of FTE Costs and Out-of-Pocket Costs for the fourth (4
th
) year of the
Research Term attached as
Exhibit C
hereto, and the terms of the Agreement shall apply to the conduct thereof.
|
|
|
c.
|
Solely with respect to Licensed Products directed to [**], the diligence provision in Section 3.2 of the Agreement shall be amended to include the following in addition to the existing diligence obligations set
forth therein:
|
|
|
i.
|
Without limiting GSK’s obligation to use Commercially Reasonable Efforts to further Develop Development Candidates directed to [**], GSK shall be required to achieve the milestone event [**]” set forth in
Section 6.5.1 as amended below (“
Specific Diligence Requirement
”) within [**] (“
Specific Diligence Period
”).
|
|
|
ii.
|
If safety issues are first identified during the Specific Diligence Period with respect to the Development Candidate in the course of performing a GLP Toxicology Study, then (1) GSK shall give EPIZYME prompt
written notice describing such safety issues in sufficient detail for EPIZYME to understand their nature, and GSK’s anticipated timeline for resolving them, and (2) the Specific Diligence Period will be suspended for such period of time as
is required to either i) resolve such safety issues with respect to such Development Candidate and progress it to the same stage of development as it was when it was determined to be unsafe for progression or ii) progress another Development
Candidate to the same stage of development as the first Development Candidate was when it was determined to be unsafe for progression.
|
|
|
iii.
|
If at the expiration of the fourth (4
th
) year of the of the Research Term, the milestone event [**] has not been achieved, then the Specific Diligence Period
shall be extended for such period of time as is required for GSK to advance the Licensed Compounds to achievement of such milestone event and GSK shall keep EPIZYME reasonably apprised of GSK’s progress toward achievement of such milestone. For
illustrative purposes only, if GSK requires [**], then the Specific Diligence Period shall be extended to cover the period commencing on the date that is [**].
|
2
|
|
iv.
|
If GSK fails to achieve the Specific Diligence Requirement within the Specific Diligence Period, then, within [**] Business Days after expiration of the Specific Diligence Period (the “
Diligence Notice
Period
”), GSK shall elect one of the following three options, and shall notify EPIZYME in writing of such election: (a) eliminate the Specific Diligence Requirement, (b) extend the Specific Diligence Period by [**], or
(c) terminate the [**] program. The following provisions shall apply to the option selected by GSK:
|
|
|
a.
|
If GSK elects to eliminate the Specific Diligence Requirement, then GSK shall pay EPIZYME [**] Dollars (US$[**]) within [**] days after receipt of an invoice from EPIZYME. Upon EPIZYME’s receipt of the payment, the
Specific Diligence Requirement shall be deemed satisfied and the corresponding milestone payment set forth in Section 6.5.1 as amended below for such Specific Diligence Requirement shall be deemed to have been paid by GSK to EPIZYME.
|
|
|
b.
|
If GSK elects to extend the Specific Diligence Period, then GSK shall pay EPIZYME [**] Dollars (US$[**]) within [**] days after receipt of an invoice from EPIZYME. Upon EPIZYME’s receipt of the payment, the
Specific Diligence Period shall be extended by [**] (“
Extended Specific Diligence Period
”).
|
|
|
c.
|
If GSK elects to terminate the [**] program, then [**] shall cease to be a Selected Target, GSK shall have no further rights under the Agreement to [**] or any Licensed Compounds directed to [**] and EPIZYME shall have
the right, at its election, to any or all of the reversion rights set forth in Section 12.5.1 of the Agreement on the terms set forth therein, with respect to [**].
|
If GSK either fails to notify EPIZYME in writing during the Diligence Notice Period of GSK’s election of one of the foregoing three
options, or GSK notifies EPIZYME in writing during the Diligence Notice Period of GSK’s election of option iv.(a) or option iv.(b) above, but GSK fails to pay the applicable payment thereunder within the applicable payment period specified
therein, then GSK shall be deemed to have elected option iv.(c).
|
|
v.
|
In the event that GSK elects option iv.(b) above and timely pays EPIZYME the [**] Dollars (US$[**]), and thereafter GSK fails to achieve the Specific Diligence Requirement within the Extended Specific Diligence Period,
then within [**] Business Days after expiration of the Extended Specific Diligence Period (the “
Extended Diligence Notice Period
”), GSK shall notify EPIZYME in writing of its election of either option iv.(a) or option iv.(c) above.
If GSK either fails to notify EPIZYME in writing during the Extended Diligence Notice Period of GSK’s election of option iv.(a) or option iv.(c), or GSK notifies EPIZYME in writing during the Extended Diligence Notice Period of GSK’s
election of option iv.(a), but GSK fails to pay the applicable payment thereunder within the applicable payment period specified therein, then GSK shall be deemed to have elected option iv.(c).
|
3
|
|
vi.
|
Paragraphs iv and v above set forth the sole and exclusive process, including GSK’s sole and exclusive liabilities and EPIZYME’s sole and exclusive remedies, for GSK’s failure to meet the Specific
Diligence Requirements for whatever reason, including lack of Commercially Reasonable Efforts, in accordance with paragraphs i, ii and iii above.
|
|
|
vii.
|
Section 3.2 of the Agreement shall remain unchanged with respect to Licensed Products directed to Selected Targets other than [**].
|
|
|
d.
|
Section 6.5.1 of the Agreement is hereby amended to provide for the payment by GSK to EPIZYME of the following non-refundable, non-creditable milestone payments upon the first achievement of the milestone events
set forth below with respect to Licensed Compounds or Licensed Products directed to [**], on the payment terms set forth in Section 6.5 and other payment provisions of the Agreement (and, for the avoidance of doubt, the provisions of Sections
6.5.2 and 6.5.3 of the Agreement shall apply to such milestone event and milestone payments, except that the reference in Section 6.5.3 to “[**]” shall be replaced with “[**]”):
|
|
|
|
|
|
Milestone Events – Table 1
|
|
Milestone Payment
($[**])
|
|
[**]
|
|
[**]
|
|
|
|
|
[**]
|
|
[**]
|
|
|
|
|
[**]
|
|
[**]
|
|
|
|
|
[**]
|
|
[**]
|
|
|
|
|
[**]
|
|
[**]
|
|
|
|
|
[**]
|
|
[**]
|
|
|
|
|
[**]
|
|
[**]
|
|
|
|
|
[**]
|
|
[**]
|
|
|
|
|
[**]
|
|
[**]
|
|
|
|
|
[**]
|
|
[**]
|
|
|
|
|
|
[**] Milestone Events – Table 2
|
|
Milestone Payment
($[**])
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
4
For clarity, the [**] for which milestones are payable under Table 2 is understood and agreed by
the Parties to mean [**] for which milestones are paid under Table 1. For illustrative purposes only, the [**], such as [**].
Solely for
purposes of the payment of milestones set forth in Table 2, “[**].
The foregoing milestone events and milestone payments are in lieu
of the milestone events and milestone payments set forth in Section 6.5.1 of the Agreement solely as they apply to Licensed Compounds and Licensed Products directed to [**];
provided that
, milestones (2) and (4) in
Section 6.5.1 of the Agreement shall remain unchanged; and
provided further that
, the milestone events and milestone payments set forth in Section 6.5.1 of the Agreement shall remain unchanged for Selected Targets other than [**]
and Licensed Compounds and Licensed Products directed to Selected Targets other than [**].
|
|
e.
|
Section 6.7 of the Agreement is hereby amended to provide for the payment by GSK to EPIZYME of the following non-refundable, non-creditable sales milestone payments upon the first achievement of the milestone
events set forth below with respect to [**], on the payment terms set forth in Section 6.7 and other payment provisions of the Agreement (except that the reference to “[**]” shall be replaced with [**]):
|
|
|
|
|
|
Sales Milestone Event
|
|
Milestone Payment
($[**])
|
|
First Calendar Year in which aggregate world-wide Net Sales of Licensed Product(s) directed to [**] are greater than or equal to
$[**]
|
|
[**]
|
|
First Calendar Year in which aggregate world-wide Net Sales of Licensed Product(s) directed to [**] are greater than or equal to
$[**]
|
|
[**]
|
|
First Calendar Year in which aggregate world-wide Net Sales of Licensed Product(s) directed [**] are greater than or equal to
$[**]
|
|
[**]
|
The foregoing milestone events and milestone payments are in lieu of the milestone events and milestone
payments set forth in Section 6.7 of the Agreement with respect to [**];
provided that
, the milestone events and milestone payments set forth in Section 6.7 of the Agreement shall remain unchanged for Licensed Products directed to
Selected Targets other than [**].
|
|
f.
|
Section 6.8.1 of the Agreement is hereby amended to provide for the payment by GSK to EPIZYME of the following incremental royalties on worldwide Annual Net Sales of Licensed Products directed to [**], on a
Licensed Product-by-Licensed Product basis, on the payment terms set forth in Section 6.8 and other payment provisions of the Agreement:
|
5
|
|
|
|
|
|
|
Worldwide Annual Net Sales
|
|
Royalty
|
|
|
Portion up to but not including $[**]
|
|
|
[**]
|
%
|
|
Portion equal to or greater than $[**] up to but not including $[**]
|
|
|
[**]
|
%
|
|
Portion equal to or greater than $[**]
|
|
|
[**]
|
%
|
The foregoing royalties are in lieu of the royalties set forth in Section 6.8.1 of the Agreement solely
with respect to Net Sales of Licensed Products directed to [**];
provided that
, the royalties set forth in Section 6.8.1 of the Agreement shall remain unchanged for Net Sales of Licensed Products directed to Selected Targets other than
[**].
4.
Termination of January 6 Letter.
This Amendment No. 3 terminates and supersedes the letter
between the Parties dated January 6, 2014 (the “
January 6 Letter
”) regarding a proposed amendment of the Agreement with respect to [**], and the subsequent letters between the Parties dated February 27, 2014 and
March 7, 2014 and March 14, 2014 extending the Interim Period (as defined in the January 6 Letter). From and after the Amendment No. 3 Effective Date, the January 6 Letter and such subsequent extension letters shall have no
further force or effect and, for the avoidance of doubt, [**] will not have ceased to be a Selected Target.
5.
Miscellaneous
. The Parties hereby confirm and agree that, as amended herein, the Agreement remains in full force and effect. This Amendment No. 3 may be executed in counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Facsimile signatures and signatures transmitted via PDF shall be treated as original signatures.
IN WITNESS WHEREOF, the Parties have caused this Amendment No. 3 to be executed by their duly authorized representatives.
|
|
|
|
|
|
|
|
|
|
|
EPIZYME, INC.
|
|
|
|
GLAXO GROUP LIMITED
|
|
|
|
|
|
|
|
By:
|
|
/s/ Jason Rhodes
|
|
|
|
By:
|
|
/s/ Paul Williamson
|
|
Name:
|
|
Jason Rhodes
|
|
|
|
Name:
|
|
Paul Williamson
|
|
Title:
|
|
President & CFO
|
|
|
|
Title:
|
|
Authorized Signatory for and on behalf of
|
|
|
|
|
|
|
|
|
|
The Wellcome Foundation Limited, Corporate Director
|
|
Date:
|
|
3/18/14
|
|
|
|
Date:
|
|
3/18/14
|
6
Exhibit A:
Amendment to DC criteria for [**] (page 1 of 2)
[**] Amended DC Criteria
|
|
|
Criteria to reach milestone
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
|
|
Criteria to reach milestone
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
Exhibit A:
Amendment to DC criteria for [**] (page 2 of 2)
[**] Amended DC Criteria
|
|
|
Criteria to reach milestone
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
|
|
Criteria to reach milestone
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
|
[**]
|
Exhibit B
|
|
|
|
|
|
|
[**]
|
|
[**]
|
|
|
|
[**]
|
|
[**]
|
|
|
|
[**]
|
|
[**]
|
|
|
|
[**]
|
|
[**]
|
|
|
|
[**]
|
|
[**]
|
|
|
|
[**]
|
|
[**]
|
|
|
|
[**]
|
|
[**]
|
|
|
|
[**]
|
|
[**]
|
|
|
|
[**]
|
|
[**]
|
|
|
|
[**]
|
|
[**]
|
|
|
Exhibit C – Page 1 of 3
[**] Research Plan Summary
Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of one page was omitted. [**]
EXHIBIT C – PAGE 2 of 3
[**] Timeline and 2014 Budget Summary
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of one page was omitted. [**]
2
EXHIBIT C – PAGE 3 of 3
[**] 2014 Budget – Detailed Summary
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of one page was omitted. [**]
3
Exhibit 99.1
Epizyme Achieves Lead Candidate Milestone for Third Target in GSK
Collaboration, Receives $4 Million in Milestone and License Payments
- Potential Therapeutic Candidates Now Identified for All Three GSK Collaboration Targets -
Cambridge, Mass.
, April 22, 2014 – Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized
therapeutics for patients with genetically defined cancers, today announced the achievement of the lead candidate milestone for the third of the three histone methyltransferase (HMT) targets in the company’s collaboration with GSK and is
receiving $4 million in milestone and license payments.
Epizyme announced the achievement of a $4 million development candidate milestone for the first
GSK collaboration target in January 2014 and a $2 million lead candidate selection milestone for the second GSK collaboration target in February 2014.
“Epizyme’s proprietary product platform is an ongoing source of potential novel therapeutic candidates for the treatment of genetically defined
cancers as we translate the science of epigenetics into innovative personalized therapeutics for cancer patients,” said Robert Copeland, Ph.D., Executive Vice President and Chief Scientific Officer, Epizyme. “Since we began our
collaboration with GSK in 2011, we have identified novel small molecule inhibitors for all three collaboration HMT targets, a significant accomplishment in a short period of time in a new therapeutic class.”
About Epizyme, Inc.
Epizyme, Inc. is a clinical stage
biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes
known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic
(cancer-causing). By focusing on the genetic drivers of cancers, Epizyme’s targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.
For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.
Cautionary Note on Forward-Looking Statements
Any
statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, development of the Company’s therapeutic candidates, and future
expectations and plans and prospects for the Company and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various
important factors, including: the uncertainties inherent in the initiation of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory
approvals, development progress of the Company’s companion diagnostics, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements, the success of the
Company’s collaborations, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates or companion diagnostics and other factors discussed in the “Risk Factors” section of the
Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2014. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date
hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
Media/Investors:
Jeff Boyle
Epizyme, Inc.
617.674.1778
jboyle@epizyme.com
Media:
Luke Dickinson
Spectrum
202.955.6222 ext. 2503
ldickinson@spectrumscience.com
Investors:
Stephanie Ascher
Stern Investor Relations
212.362.1200
stephanie@sternir.com